The Colombia-based operations of cannabis cultivator, global brand builder and product distributor Flora Growth (NASDAQ: FLGC) are receiving increased attention from market watchers, particularly in the wake of the company’s announcement that it executed a letter of intent (“LOI”) with Australia’s Evergreen Pharmacare Pty Ltd. to supply medical-grade dried flower and derivative cannabis products to Australians through Evergreen’s pharmacy distribution network.
A July 27 statement issued by Flora Growth indicated Evergreen helps patients and healthcare practitioners, primarily physicians and pharmacists, obtain medical cannabis products and provides them with additional cannabis-related education about its use, authorization and regulation. Flora Growth will begin shipping its medical-grade cannabis products as soon as it harvests its first commercial crop and secures the necessary export licenses (https://cnw.fm/YefTQ).
Market analysts at FreshLeaf Analytics (https://cnw.fm/ValZP) and Prohibition Partners (https://cnw.fm/Ob8Ab) predict the medical cannabis segment will range in value from about US$150 million this year to up to US$1.5 billion by 2025, and the LOI between Flora Growth and Evergreen positions the Colombian grower (with headquarters in Miami, Florida) at the leading edge of a burgeoning market.
“This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market,” Chief Revenue Officer Jason Warnock stated in the company’s news release, adding that Australian regulators’ recent decision to down-schedule cannabidiol (“CBD”) to a level where it can be sold as an over-the-counter product opens the door to Flora’s strategy for “providing proven cannabinoid wellness and beauty products to consumers around the world.”
Flora Growth also recently announced that it has signed an LOI to form a joint venture with Canadian-based Avaria Inc., which manufactures pain cream under its flagship brand KaLaya. KaLaya is distributed nationwide across Canada and anticipates distribution across Latin American countries under the JV, with exports to the United States as Flora Growth manages registration, sales and distribution needs. The upside here is not only bringing these well-received products to international markets, but to also infuse these products with cannabinoids, particularly CBD, in order to generate incremental revenue.
Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale, so the partnership would see Flora Growth’s lab division providing it with a necessary boost to expand its market reach as it supplies the cannabis derivative products and low-cost manufacturing locally in Colombia.
In Canada, KaLaya has been recognized as the most popular topical analgesic brand distributed through Canadian retailer Purity Life and by The Shopping Channel in 2020, weighing in as Canada’s fastest growing topical decongestants and analgesics brand, according to Nielsen Market Track.
“Given CBD’s association with wellness, KaLaya’s established formulation, and Flora Growth’s low-cost high-quality cannabis, this is a natural partnership we are excited to bring globally,” Flora Growth President and CEO Luis Merchan stated in the news release.
For more information, visit the company’s website at www.FloraGrowth.ca.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC
About HempWire
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
HempWire is part of the InvestorBrandNetwork.
Legislators in states across the country are working towards strictly regulating and/or banning intoxicating hemp…
A proposal introduced by Sen. Colleen Burton that would ban delta-8 THC hemp products is…
California recently extended a ban on intoxicating hemp products with THC that was set to…
A new poll has determined that frequent consumers of marijuana like using delivery platforms to…
The demand for plant-based proteins has increased in the last couple of years as consumer…
The CBD market in the United Kingdom has grown since the compound’s extracts were designated…